Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Ensure that there is...

    Ensure that there is no hoarding, blackmarketing of medicines: NPPA chief tells states on Covid-19 outbreak

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-27T15:00:52+05:30  |  Updated On 27 Feb 2020 5:32 PM IST
    Ensure that there is no hoarding, blackmarketing of medicines: NPPA chief tells states on Covid-19 outbreak

    State Governments and UTs are requested to closely monitor the production and availability of APIs and their formulations to prevent black marketing and hoarding

    New Delhi: Taking strong measures in the light of coronavirus outbreak the apex drug price regulator National Pharmaceutical Pricing Authority (NPPA) has written to all the states and union territories asking them to ensure that there is no shortage of drugs and APIs in their areas due to black marketing and hoarding

    National Pharmaceutical Pricing Authority (NPPA) Chairman Shubhra Singh has recently written to the chief secretaries of all States and Union Territories to monitor the availability of APIs and drugs in the context of the outbreak of COVID-19 in China. WHO has since declared the situation as Global Health emergency.

    "It is widely known that India is the Pharmacy of the World. However, India is heavily dependent on China for import of key APIs and KSM and there is an apprehension that in wake of COVID-19 the supplies of Active Pharmaceutical Ingredients (APIs) / Key Starting Materials (KSM) from China might be disrupted, resulting in a shortage of medicines in the country," the letter noted

    "As you are aware, Drugs are an essential commodity under the Essential Commodities Act, 1955. Further, the National Pharmaceutical Pricing Authority (NPPA) was constituted vide Government Resolution dated 29th August 1997 as an attached office of the Department of Pharmaceuticals, Ministry of Chemical & Fertilizers, Government of India to function as the National Regulator for pricing of drugs and to ensure availability and accessibility of affordable medicines. The NPPA implements the Drugs (Prices Control) Orders (DPCO) issued by the Government from time to time." the letter added

    NPPA chief further observed that key Drug Industry Associations have assured the Government that there is enough stock of APIs/ formulations in the country.

    Read also: NPPA fixes price of 21 formulations including diabetes drugs, others; Details

    "However, as a measure of public health preparedness in respect of APIs/Intermediates/KSMs which are imported from China, State Governments and UTs are requested to closely monitor the production and availability of APIs and their formulations to prevent black marketing and hoarding," she said

    "It may also be ensured that there is no violation of provisions of DPCO, 2013 with regard to compliance of ceiling prices / permissible increase in prices of scheduled / non-scheduled formulations. In case any contravention is noticed, necessary action should be taken under the provisions of DPCO, 2013 to ensure availability of life-saving essential drugs to the consumers at all times under intimation to this office," she furhter added

    Read also: Violation of price capping of Coronary stent to attract NPPA action; Minister

    covidcoronavirusnational-pharmaceutical-pricing-authorityActive Pharmaceutical Ingredientshoardingblackmarketing

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok